[Risk factors for the occurrence of bronchiolitis obliterans in children with refractory Mycoplasma pneumoniae pneumonia and the predictive value of the factors]. [PDF]
Cheng GL, Xu BX, Jia L.
europepmc +1 more source
[Construction of a risk prediction model for bronchiolitis obliterans in children with refractory Mycoplasma pneumoniae pneumonia]. [PDF]
Liu TH, Liu XX, Tang Y, Qi F, Liu DP.
europepmc +1 more source
[Risk Factors and Prognosis of Pneumoconiosis Combined With Bacterial Pneumonia: Application of a Random Forest Model]. [PDF]
Wang Q +5 more
europepmc +1 more source
[Efficacy of prolonged azithromycin versus switching to doxycycline in the treatment of macrolide-unresponsive Mycoplasma pneumoniae pneumonia in children]. [PDF]
Ma YC, Zhou XH, Zhao XD, Wang CY.
europepmc +1 more source
[<i>Xuebijing</i> Injection in synergy with linezolid alleviates inflammatory injury in mice with MRSA pneumonia by inhibiting the Hla-NLRP3 pathway]. [PDF]
Yin M, Li R, Yang K, Jiao W, Liu X.
europepmc +1 more source
本症例ハ瓣状ノ氣胸ニシテ、而モ兩側肋膜腔内ニハ些少ノ滲出液ヲモ容レザル眞ノ氣胸例ナリトス、而シテ本症例ニ於テ氣胸ヲ起シタル原因ヲ尋ヌルニ、本患者ハ臨牀上ビルケー氏反應陰性ニシテ、且病理解剖上何處ニモ結核性病竈ヲ證明セザリシヲ以テ見レバ、結核ニ原因シタルモノニアラザルヲ知ル、而シテ病理解剖上兩肺ニ於ケル肺氣腫、氣管枝擴張、慢性間質性肺炎等ノ存スル點ヨリ見レバ、患兒ハ發病一箇月前ニ毛細氣管枝炎ヲ患ヒ、其ノ際全治ニ至ラズシテ間質性肺炎ヲ續發シ、次デ代償性ニ肺氣腫乃至氣管枝擴張ヲ惹起シ ...
池田, 嘉一郎
core
[Epidemiological characteristics of human metapneumovirus and risk factors for severe pneumonia in hospitalized children]. [PDF]
Wang YX +5 more
europepmc +1 more source
[Value of calprotectin S100 A8/A9 in predicting the severity of Mycoplasma pneumoniae pneumonia in children]. [PDF]
Zhou P +5 more
europepmc +1 more source
マウスのブレオマイシン肺臓炎モデルにおけるアラキドン酸代謝産物の関与
1996226909マウスBLM肺線維症モデルに対する,AAMの拮抗剤及び類似物質投与の影響を検討した. 1)TXA2受容体拮抗剤S-1452は,BLMによる肺臓炎の形成を用量依存的に有意に抑制した. 2)pLT受容体拮抗剤AS-35は,BLMによる肺臓炎の形成を用量依存的に有意に抑制した. 3)PGE1の誘導体であるPGE1αCDは,BLMによる肺臓炎の形成を用量依存的に有意に抑制した.
野村, 将春
core
[Risk factors for plastic bronchitis in children with macrolide-unresponsive <i>Mycoplasma pneumoniae</i> pneumonia and establishment of a nomogram model]. [PDF]
Shi XS, He XH, Chen J.
europepmc +1 more source

